Introduction
============

Lung cancer is a malignant disease with the highest morbidity and mortality worldwide in recent years ([@ref-5]). Eighty-five percent of lung cancers are non-small cell lung cancer (NSCLC), which can be divided into lung adenocarcinomas (LUAD) and squamous carcinomas ([@ref-21]). There has been an increase in the incidence of LUADs, accounting for 60% of NSCLCs and the most common type of lung cancer ([@ref-10]). The 5-year survival rate of patients with early-stage NSCLC after surgical treatment is 70%--90%; however, approximately 75% of patients lost their opportunity for surgery by the time of initial diagnosis ([@ref-15]). Despite important advances in targeted molecular therapies and immunotherapy for lung cancer, drug resistance still limits success ([@ref-2]), and new biomarkers are warranted for different populations. This will have important implications for improving patients' early diagnosis rates and for discovering novel targeted therapies.

In addition to tumor cells, stromal cells and immune cells as well as tumor-associated normal epithelial cells form malignant solid tumor tissues ([@ref-26]). Stromal cells contain cancer-related fibroblasts, pericytes, mesenchymal stem cells, blood, and lymphatic endothelial cells ([@ref-28]). In the tumor microenvironment (TME), stromal cell components and tumor cells interact with other to establish a dynamic connection, which affects the biological function and chemical resistance of tumor cells ([@ref-18]). Four types of immune cells are relevant: tumor infiltrating lymphocytes (TILs), tumor-associated macrophages, myeloid-derived suppressor cells, and dendritic cells ([@ref-3]). TILs play an important role in immune surveillance and killing of cancerous cells in patients with lung cancer ([@ref-38]). NK cell-mediated tumor suppressor function is closely related to tumor progression and is a key factor regulating lung cancer growth and metastasis ([@ref-11]). Depicting the immune infiltration of tumor microenvironment or determining the proportion of relevant normal cells in tumor tissues can help in building an accurate tumor prognosis and prediction model. [@ref-16] demonstrated that chondroitin sulfate proteoglycan serglycin (SRGN), which is secreted by tumor cells and stromal components in the TME, promotes malignant phenotypes through interacting with tumor cell receptor CD44. Increased expression of SRGN is associated with poor prognosis in primary LUAD ([@ref-16]). Galectin-3 is a lectin that contributes to TME immunosuppression and regulates diverse functions. Studies suggest that increased Gal-3 expression during cancer progression augments tumor growth, invasiveness, metastatic potential, and immune suppression ([@ref-9]; [@ref-12])

The quantification of various cell types allows accurate analysis of dynamically changing immune microenvironments. Experimental methods, such as single-cell sequencing ([@ref-20]), are expensive and cumbersome to operate; therefore, various algorithms have been developed to describe tumor immune environments, including single-sample gene set enrichment analysis (GSEA) ([@ref-13]), MCPcounter ([@ref-27]), and CIBERSORT ([@ref-8]). [@ref-39] proposed a new algorithm known as ESTIMATE that uses expression data to estimate the number of immune and stromal cells in malignant tumor tissues. This algorithm focuses on the formation of immune and stromal cells from major non-tumor components of tumor samples and identifies the stromal and tumor tissue-specific characteristics associated with immune cell infiltration. Its effectiveness has been shown in glioblastoma ([@ref-17]) and breast cancer ([@ref-36]). Although accurate immune and stromal scoring of LUAD can be performed, there have been no detailed studies that have analyzed related the expression profiles with ESTIMATE. In this study, the microenvironment-related genes of the LUAD cohort of the TCGA database were studied based on the ESTIMATE score, and the prognostic genes of three different LUAD cohorts from the GEO database were verified. To further elucidate the immunological mechanisms, we assessed the role of the immune microenvironment in the development of LUAD using immune/stromal cell infiltration analysis.

Material and Methods
====================

Database
--------

The level 3 gene expression profile data of lung adenocarcinoma patients (using Illumina HiSeq_RNASeqV2 lung adenocarcinoma RNA expression profiles) were downloaded from the TCGA website (<https://portal.gdc.cancer.gov/>). The immune and stromal scores were calculated from each sample using the ESTIMATE algorithm. In addition, patient clinical data were downloaded from the TCGA official website (<https://portal.gdc.cancer.gov/repository>). The LUAD gene chip expression profile data and the clinical data ([GSE37745](GSE37745), [GSE11969](GSE11969), and [GSE50081](GSE50081)) of the samples were downloaded from the GEO official website (<https://www.ncbi.nlm.nih.gov/geo/>) for subsequent validation analysis. To analyze the mRNA/protein expression of CCR6 in primary LUAD and normal tissues, UALCAN (<http://ualcan.path.uab.edu>) was used, which was based on the TCGA database and Clinical Proteomic Tumor Analysis Consortium. To validate the expression of CCR6, the Human Protein Atlas (<http://www.proteinatlas.org/>) was used. Tumor Immune Estimation Resource (TIMER) (<https://cistrome.shinyapps.io/timer/>) was used to assess the correlation between differentially expressed gene (DEG) expression and the immune cell infiltration level. Immune cell infiltration was evaluated using the TIMER and CIBERSORT method, and stromal cell infiltration was determined using xCell (<https://xcell.ucsf.edu/>).

Identification of differentially expressed genes (DEGs)
-------------------------------------------------------

The limma package in R was used for the analysis of differential expression genes ([@ref-30]), and the cutoff value was set to ---log fold change(FC)--- \> 1, and a *p* value \< 0.05. We plotted a heat map using the cluster analysis results of DEGs in R.

GO and KEGG enrichment analysis
-------------------------------

To investigate the molecular functions, biological processes, cell components, and signaling pathways involved in DEGs, we used the DAVID database (v6.8, <https://david.ncifcrf.gov/>) to perform GO analysis and KEGG pathway enrichment. *p* value \< 0.05 and FDR \< 0.05 were marked as significant terms.

Statistical analysis
--------------------

The data were assessed for normal distribution, and the central tendency was expressed as the mean ± standard deviation for the data with normal distribution. Means were compared using a Student's *t*-test. Continuous variables that did not have normal distribution were analyzed using the Wilcoxon rank sum test or Kruskal--Wallis rank sum test. Student's t-tests were used to compare the distribution of scores in the high and low groups, gender, and M stages. The Wilcoxon rank sum test was used to compare the distribution of scores in age, T stages, and N stages. The Kruskal--Wallis rank sum test was used to compare the differences in the distribution of scores of the four different pathological stages. Spearman's rank correlation coefficient was used to measure the correlation between lung cancer stage and overall survival. Determination of survival-related genes was performed using univariate Cox regression analysis (with a *p* value of \< 0.05) and the corresponding survival curves were plotted. Multivariate Cox analysis was used to evaluate the contribution of genes as independent prognosis factors for patient survival. All tests were two-tailed, and *p* values less than 0.05 were considered statistically significant. Al analyses were performed using SPSS for Windows, software version 25.0 (SPSS Inc., Chicago, IL).

Results
=======

Correlation between immune and stromal scores and clinical characteristics of LUAD
----------------------------------------------------------------------------------

We downloaded the gene expression profiles and clinical data of 492 patients with LUAD from the TCGA database, including 225 males (45.7%), 267 females (54.3%), 157 patients under 60 years of age (31.9%), and 335 patients over 60 years of age (68.1%). The ESTIMATE algorithm revealed stromal scores of −1959.31 to 2989.77, and the immune scores of −1355.85 to 2905.3. The results of the relationship between the two scores and clinical data (TNM and pathological stage) are shown in [Table 1](#table-1){ref-type="table"}. There were differences in the distribution of stromal scores between the sexes and across M stages. Immune scores also differed with respect to T and pathological stages.
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###### The relationship between the two scores and clinical characteristics.

![](peerj-08-9530-g009)

  Variable         Patients   Stromal scores     *P* value                                     Immune scores    *P* value
  ---------------- ---------- ------------------ --------------------------------------------- ---------------- ---------------------------------------------
  **Scores**                                     \<0.000[^\*\*^](#table-1fn2){ref-type="fn"}                    \<0.000[^\*\*^](#table-1fn2){ref-type="fn"}
  Low              246        −539.40 ± 27.69                                                  490.60 ± 45.44   
  High             246        635 ± 26.75                                                      1437 ± 41.31     
  **Age, years**                                 0.223                                                          0.100
  ≥60              157        235.10                                                           231.1            
  \>60             335        251.84                                                           253.72           
  **Sex**                                        0.007[^\*\*^](#table-1fn2){ref-type="fn"}                      0.005[^\*\*^](#table-1fn2){ref-type="fn"}
  Male             225        −48.34 ± 48.91                                                   849.60 ± 55.64   
  Female           267        128.80 ± 43.52                                                   1060 ± 49.79     
  **T stage**                                    0.101                                                          0.001[^\*\*^](#table-1fn2){ref-type="fn"}
  T1               167        260.99                                                           277              
  T2/T3/T4         325        238.85                                                           230.40           
  **N stage**                                    0.768                                                          0.155
  N0               318        242.34                                                           247.45           
  N1/N2/N3         163        238.39                                                           228.42           
  **M stage**                                    0.010[^\*\*^](#table-1fn2){ref-type="fn"}                      0.037[^\*^](#table-1fn1){ref-type="fn"}
  M0               324        54.67 ± 40.45                                                    961.70 ± 46.01   
  M1               24         −343.60 ± 137.40                                                 592.90 ± 177.2   
  **Stage**                                      0.137                                                          0.023[^\*^](#table-1fn1){ref-type="fn"}
  I                262        249.35                                                           256.45           
  II               118        246.36                                                           242.92           
  III              79         232.61                                                           210.16           
  IV               25         183.72                                                           196.48           

**Notes.**

*p* \< 0.05.

*p* \< 0.01.

We found that the immune and stromal scores of female patients were significantly higher than those of from male patients (*p* = 0.0069 and 0.0049, respectively) ([Figs. 1A](#fig-1){ref-type="fig"} and [1B](#fig-1){ref-type="fig"}). The immune score of T1 was significantly higher than that of T2/T3/T4 stages (*p* = 0.0002, [Fig. 1C](#fig-1){ref-type="fig"}); however, but the distribution of stromal scores was not different between the two groups (*p* = 0.0999) ([Fig. 1D](#fig-1){ref-type="fig"}). The immune and stromal scores of the M0 stage was higher than those of the M1 stage (*p* = 0.0098 and 0.0366, respectively) ([Figs. 1E](#fig-1){ref-type="fig"} and [1F](#fig-1){ref-type="fig"}). For the different pathological stages of LUAD, the immune scores were different at each stage (*p* = 0.0276, [Fig. 1G](#fig-1){ref-type="fig"}) and gradually decreased from stage I to stage IV (Spearman correlation coefficients: *ρ* = −0.131, *p* = 0.004); however, but the difference in stromal scores among the four pathological stages was not statistically significant (*p* = 0.1525, [Fig. 1H](#fig-1){ref-type="fig"}).

![Relationships among immune and stromal scores, clinical characteristics, and overall survival.\
Distribution of stromal and immune scores based on gender (A), T stage (B), M stage (C) , and pathological stage (D). Kaplan--Meier survival analysis of low and high score groups based on stromal (E) and immune scores (F). (\* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001).](peerj-08-9530-g001){#fig-1}

Next, we evaluated the correlations between immune (or stromal) scores and overall survival. LUADs (*N* = 492) were divided into high- and low-score groups, with 246 cases in each group. Stromal scores ranged from −959.31 to 36.85 for the low group and from 39.8 to 2098.77 for the high group. Immune scores ranged from −1355.85 to 952.61 for the low group and 964.93 to 2905.3 for the high group. The Kaplan--Meier survival curve analysis for immune scores indicated that the median survival of the low-score group was lower than that of the high-score group (1194 d vs. 1499 d, *p* = 0.011; log-rank test; [Fig. 1I](#fig-1){ref-type="fig"}). Similarly, for stromal scores, the median survival of the low-score group was lower than that of the high-score group (1235 d vs. 1492 d, *p* = 0.179; log-rank test; [Fig. 1J](#fig-1){ref-type="fig"}), although it was not statistically significant.

Comparison of gene expression profiles with LUAD immune scores and stromal scores
---------------------------------------------------------------------------------

We performed differential expression analysis of the high- and low- immune scoring patients and found that 884 genes were downregulated and 55 genes were upregulated ([Fig. 2A](#fig-2){ref-type="fig"}, [Table S1](#supp-1){ref-type="supplementary-material"}). Similarly, differential analysis of the high- and low-stromal scoring groups revealed that 999 genes were downregulated and 28 genes were up-regulated (---logFC---\>1, *p* \< 0.05) ([Fig. 2B](#fig-2){ref-type="fig"}, [Table S1](#supp-1){ref-type="supplementary-material"}). In the Venn diagram, 18 genes were found to be upregulated in both groups ([Fig. 2C](#fig-2){ref-type="fig"}) and 512 genes were downregulated in both groups ([Fig. 2D](#fig-2){ref-type="fig"}).

![Comparison of gene expression profiles with immune scores and stromal scores in LUAD.\
Heatmaps were drawn for the DEGs obtained from the respective high and low group comparisons of the immune scores (A) and stromal scores (B). Venn diagrams drawn from the DEGs that are up- or down-regulated in immune scores (C) and stromal scores (D).](peerj-08-9530-g002){#fig-2}

Correlation of individual DEGs expression with overall survival and Functional enrichment analysis of prognostic associated genes
---------------------------------------------------------------------------------------------------------------------------------

To explore the DEGs associated with overall survival, we performed a univariate Cox regression analysis. The results ([Table S2](#supp-2){ref-type="supplementary-material"}) showed that 286 of the 530 DEGs were survival-related genes (*p* \< 0.05). To further determine the relationship between these prognostic DEGs, we used the STRING online tool to obtain a PPI network. This network has 277 nodes and 2143 edges ([Fig. 3](#fig-3){ref-type="fig"}). Functional enrichment clustering of 286 prognostic DEGs was also closely related to the immune pathways. GO analysis results showed that 46 terms were statistically significant, and KEGG enrichment results showed that 22 pathways were significantly enriched (*p* \< 0.05, FDR \<0.05). The top GO terms included adaptive immune response, T cell co-stimulation, MHC class II receptor activity, and transmembrane signaling receptor activity ([Fig. 4A](#fig-4){ref-type="fig"}). In addition, most pathways generated from the KEGG pathway enrichment analysis were associated with immune responses, such as cell adhesion molecules, primary immunodeficiency, antigen processing and presentation, and chemokine signaling pathways ([Fig. 4B](#fig-4){ref-type="fig"}).

![PPI network of 286 prognostic DEGs.](peerj-08-9530-g003){#fig-3}

![GO term and KEGG analysis of 286 DEGs.\
(A) GO analysis of 286 DEGs. (B) KEGG enrichments of 286 DEGs. GO --gene ontology; KEGG --Kyoto Encyclopedia of Genes and Genomes; MF --molecular function; CC --cellular component; BP --biological process.](peerj-08-9530-g004){#fig-4}

Further identification of prognostic genes in the GEO database
--------------------------------------------------------------

To confirm whether the genes identified in the above steps have prognostic functions in other LUAD cohorts, we used the expression profiles and clinical data of three datasets in the GEO database for verification: [GSE37745](GSE37745), [GSE11969](GSE11969), and [GSE50081](GSE50081). A total of 80 genes in [GSE37745](GSE37745), 2703 genes in [GSE11969](GSE11969), and 34 genes in [GSE50081](GSE50081) were associated with survival. CSF2RB, inducible T cell kinase (ITK), and FLT3, and CD79A were found to be common among the [GSE37745](GSE37745), [GSE11969](GSE11969), and TCGA datasets ([Fig. 5A](#fig-5){ref-type="fig"}). In addition, CCR4, CCR6, DOK2, AMPD1, and IGJ were found to be common among [GSE37745](GSE37745), [GSE50081](GSE50081), and TCGA ([Fig. 5B](#fig-5){ref-type="fig"}). Kaplan--Meier survival curves were generated for the nine prognostic genes ([Fig. 5C](#fig-5){ref-type="fig"}). The results showed that for all but except CCR4, the overall survival time of the low expression group was significantly lower than that of the high expression group (log-rank *p* \< 0.05). This suggests that reduced expression of the eight genes (CSF2RB, ITK, FLT3, CD79A, CCR6, DOK2, AMPD1, and IGJ) and increased expression of one gene (CCR4) can predict poor survival of patients with for LUAD.

![Correlation between expression of nine prognosis-related genes and overall survival in GEO.\
(A) The Venn diagram shows prognosis-related genes based on [GSE11969](GSE11969), [GSE37745](GSE37745) and TCGA cross-validation. (B) The Venn diagram shows prognosis-related genes based on [GSE50081](GSE50081), [GSE37745](GSE37745), and TCGA cross-validation. (C) Kaplan--Meier survival curves were generated for nine prognosis genes (AMP11, CCR4, CCR6, CD79A, CSF2RB, DOK2, FLT3, IGJ, and ITK) extracted from the comparison of groups of high (red line) and low (blue line) gene expression.](peerj-08-9530-g005){#fig-5}

Immune cell infiltration analysis revealed the correlation between the expression of the DEGs and immunocytes
-------------------------------------------------------------------------------------------------------------

To confirm these findings, we used multivariate Cox regression and found that the five genes, including CCR6, ITK, CCR4, DOK2, and AMPD1, were an independent prognostic indicator for LUAD in their specific data sets ([Figs. 6A](#fig-6){ref-type="fig"}--[6D](#fig-6){ref-type="fig"}). We investigated immune infiltration using the TIMER deconvolution approach. Interestingly, the expression of the five genes identified positively correlated to the infiltration level of different immune cells, including B cells, CD4^+^ T cells, CD8^+^ T cells, macrophage cells, neutrophil cells, and dendritic cells (*p* \<0.05). The expression levels of the five genes were negatively correlated with the tumor purity (*p* \< 0.05; [Figs. 7A](#fig-7){ref-type="fig"}--[7II](#fig-7){ref-type="fig"}).

![The multivariate Cox regression analysis of 9 prognostic genes.\
The HR and *P*-value from the multivariate Cox regression of selected prognostic genes in TCGA (A), GSE11969 (B), GSE37745 (C), GSE50081 (D). (\* *p* \< 0.05, \*\* *p* \< 0.01).](peerj-08-9530-g006){#fig-6}

![Correlation analysis between the expressions of mainly identified DEGs (CCR6, ITK, CCR4, DOK2, AMPD1) and infiltration levels of B cell, CD8+ T cell, CD4+ T cell, macrophage, neutrophil, and dendritic cell.](peerj-08-9530-g007){#fig-7}

![mRNA and protein expressions, immune and stromal status of CCR6 in LUAD.\
(A) mRNA and protein expressions of CCR6 in primary LUAD tissues compared to normal samples (UALCAN). (B) CCR6 protein were not expressed in normal lung tissues, whereas its high expressions were observed in LUAD tissues (The Human Protein Atlas). (C) Bar charts of 22 immune cell proportions (CIBERSORT) and 14 stromal cell proportions (xCell) between low and high expression of CCR6 in LUAD. (D) Differential expression of different types of immune cells and stromal cells between low and high expression of CCR6 in LUAD. (E) The association of SCNAs of CCR6 with immune infiltration in LUAD (TIMER).](peerj-08-9530-g008){#fig-8}

Evaluation of the immune and stromal status between the groups with low and high expression of CCR6
---------------------------------------------------------------------------------------------------

Multivariate Cox regression analysis identified that low expression of CCR6 is an independent prognostic factor of poor survival in the TCGA cohort of 484 patients with LUAD (HR 0.29, 95 % CI \[0.12--0.72\], *p* = 0.007). According to the results of UALCAN, mRNA and protein expression of CCR6 were all significantly upregulated in primary LUAD tissues as compared with normal samples (all *p* \< 0.05; [Figs. 8A](#fig-8){ref-type="fig"} and [8B](#fig-8){ref-type="fig"}). Immunohistochemistry staining obtained from The Human Protein Atlas database also demonstrated that CCR6 was upregulated ([Figs. 8C](#fig-8){ref-type="fig"} and [8D](#fig-8){ref-type="fig"}). According to the median value of CCR6 expression levels, we divided the 484 LUAD patients into a low expression group and a high expression group. CIBERSORT and xCell were used to depict the immune cell and stromal cell landscape of CCR6 with high and low expression levels. [Figs. 8E](#fig-8){ref-type="fig"} and [8F](#fig-8){ref-type="fig"} show the proportions of immune cells and stromal cells in the 484 LUAD tissues. The differential proportion of infiltration of immune and stromal cells in the group with low CCR6 expression and the group with high CCR6 expression is shown in [Figs. 8G](#fig-8){ref-type="fig"} and [8H](#fig-8){ref-type="fig"}. CIBERSORT analysis suggests that high CCR6 expression is associated with recruitment of memory B cells, resting memory CD4 T cells, monocytes, M1 macrophages, resting dendritic cells, and resting mast cells ([Fig. S1](#supp-3){ref-type="supplementary-material"}). xCell analysis suggests that high CCR6 expression is associated with recruitment of adipocytes, chondrocytes, endothelial cells, and fibroblasts ([Fig. S1](#supp-3){ref-type="supplementary-material"}). A comparison of the tumor infiltration levels among tumors with different somatic copy number alterations (SCNAs) for a given gene was determined using TIMER. The results showed that enrichment of the six immune cell types (B cell, CD4^+^ T cell, CD8^+^ T cell, macrophage cell, neutrophil cell, and dendritic cell) were significantly downregulated in LUAD with SCNA of CCR6 ([Fig. 8I](#fig-8){ref-type="fig"}).

Discussion
==========

Previous studies have shown that the TME can play a key role in promoting tumor progression and increasing mortality ([@ref-6]; [@ref-37]). From the perspective of the TME, we identified a series of genes related to the overall survival of patients with LUAD based on data in the TCGA database. By analyzing differences in the overall expression profiles of patients of LUAD cases in high and low scoring groups using the ESTIMATE algorithm, we identified 286 prognostic genes involved in immune response and chemokine signaling. Importantly, we validated these results using three independent LUAD datasets from the GEO database. From the overlap among these datasets, we obtained nine prognostic genes that were associated with the immune microenvironment of LUAD. We found that five (ITK, DOK2, AMPD1, CCR4, and CCR6) out of nine genes were prognostic factors for LUAD in their specific data set.

Abnormal expression of protein tyrosine kinases (PTK) is related to tumor invasion and metastasis, tumor neovascularization, and tumor chemotherapy resistance ([@ref-19]). Many drugs have been developed to target PTKs. Although tyrosine kinase inhibitors (TKIs) continue to be involved in targeted therapies for lung cancer, acquired resistance still remains a problem ([@ref-1]). It has been suggested that the mechanism of action of different PTKs needs additional study. IL2 inducible T cell kinase (ITK) is expressed in many immune cells. As a non-receptor tyrosine kinase, it plays an important role in regulating TCRs, chemokine receptor CXCR4, and FC εR-mediated signaling pathways ([@ref-31]). The proteins downstream of tyrosine kinase participate in the proliferation and migration of lung cancer ([@ref-14]), leukemia ([@ref-35]), gastric cancer ([@ref-22]), and other cancer cells via the receptor tyrosine kinase signaling pathway. A study has found that DOK2 is a tumor suppressor gene in LUAD and that knocking out Dok2 in mice accelerates lung tumorigenesis induced by oncogenic EGFR ([@ref-4]). We found that low expression levels of ITK, and DOK2 in LUAD were associated with poor prognosis, possibly affecting tumor progression via the transmembrane receptor PTK signaling pathway. However, further studies are required to determine whether TKI can become a new target for lung cancer.

The AMPD1 gene encodes adenosine monophosphate deaminase (AMPD), a crucial enzyme in purine nucleotide and energy metabolism, especially in skeletal muscle and cardiac muscle. The role of AMPD1 is to catalyze the conversion of adenosine monophosphate to inosine monophosphate ([@ref-33]). [@ref-24] identified that AMPD1 was closely associated with the survival of breast cancer patients. [@ref-40] found that the expression of AMPD1 in serum of patients with papillary thyroid carcinoma is closely related to the malignant evolution of PTC and clinical prognosis of patients. The relationship between AMPD1 and LUAD has not previously been elucidated.

Functional enrichment analysis showed that CCR6 was significantly involved in the chemokine signaling pathway. This is consistent with results from previous studies that indicate that in the TME, the communication among cells is dynamically regulated by a complex network of immune factors, including cytokines, chemokines, and numerous growth factors ([@ref-32]). A variety of chemokines promote tumor proliferation, which can play a vital role in tumor progression by helping tumor cells escape immune monitoring ([@ref-7]).

We found that low expression of CCR6 and high expression of CCR4 were significantly associated with poor prognosis of LUAD, based on a multi-cohort study. Multivariate Cox analysis suggests that CCR6 is an independent prognostic factor in the TCGA LUAD cohort and that CCR4 is an independent prognostic indicator in the two LUAD cohorts, [GSE50081](GSE50081) and [GSE37745](GSE37745). [@ref-23] also found that CCR4 is an independent risk factor for the overall survival of NSCLC, as it functions as a ligand for CCL17 and CCL22. CCR4 can help tumor cells escape the host immune attack by attracting Treg into the TME. Studies have identified that CCR6 can act as a ligand for CCL20 and promote lung metastasis of cancerous adrenal tissue ([@ref-29]). In a mouse model of lung cancer (Lewis lung carcinoma), expression of CCR6 in tumor cells reduced metastatic potential ([@ref-34]). Similar to our findings, a study found that increased expression of CCR6 in tumor cells is an independent predictor of a better prognosis in patients with LUAD ([@ref-25]). A recent study showed that CCL20, in coordination with CCR6, can recruit Treg cells to tumor sites ([@ref-41]). To our knowledge, we have for the first time depicted the landscape of immune cell infiltration and the landscape of CCR6 in stromal cells in LUAD. Our results also suggest that there is a close correlation between CCR6 genomic alterations and immune cell enrichments in LUAD. Therefore, we hypothesized that genetic alteration of CCR6 may play an important role in LUAD. Consistent with both of these previous studies, our analysis reveals an important role of CCR6 in LUAD and its potential value as a biomarker.

Conclusions
===========

In conclusion, using the ESTIMATE algorithm, TIMER, CIBERSORT, and xCell, we analyzed the expression profile data of patients with LUAD from the TCGA database and identified a series of genes related to the TME. Many previously unknown genes were found in addition to the genes already associated with lung cancer or immune microenvironments. Finally, we examined the interaction between CCR6 and TME. This may be important to identify the connecting mechanism between TME and LUAD prognosis.
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